MyFinsight
Home
Blog
About
Proceeds from exercise of
stock options
$1,679K
(-76.84%↓ Y/Y)
Proceeds from issuance of
common stock pursuant...
$902K
(26.51%↑ Y/Y)
Net cash provided by
financing activities
$2,581K
(-97.47%↓ Y/Y)
Net decrease in
cash, cash...
-$68,058K
(-6930.79%↓ Y/Y)
Canceled cashflow
$2,581K
Stock-based compensation
expense
$14,649K
(-27.24%↓ Y/Y)
Loss (gain) on
disposal of items of...
-$4,866K
Depreciation and
amortization expense
$1,851K
(-7.77%↓ Y/Y)
Accrued expenses
$1,471K
(163.85%↑ Y/Y)
Operating lease assets
-$675K
(-988.71%↓ Y/Y)
Non-cash interest
expense
$640K
(-70.15%↓ Y/Y)
Accounts payable
$196K
(-88.72%↓ Y/Y)
Net cash used in
operating activities
-$67,272K
(32.67%↑ Y/Y)
Net cash used in
investing activities
-$3,367K
(-10.47%↓ Y/Y)
Canceled cashflow
$24,348K
Revenue
$13,475K
Interest income
$5,450K
Other non-operating
items
$689K
Net loss
-$78,763K
(40.27%↑ Y/Y)
Purchases of property and
equipment
$3,367K
(5.95%↑ Y/Y)
Canceled cashflow
$19,614K
Accounts receivable, net
$5,914K
(399.29%↑ Y/Y)
something is missing
-$4,866K
Operating lease
liabilities
-$812K
(-231.43%↓ Y/Y)
Change in fair value of
derivative liabilities
$689K
(142.56%↑ Y/Y)
Prepaid expenses and
other current assets
$487K
(109.77%↑ Y/Y)
Inventory
$89K
(9000.00%↑ Y/Y)
Axpaxli
$28,756K
Selling and marketing
$15,078K
Stock-based compensation
$14,649K
General and
administrative
$14,416K
Unallocated expenses,
personnel costs
$13,538K
Interest expense
$2,792K
Facilities
$2,488K
Unallocated expenses, all
other costs
$2,081K
Cost of product
revenue
$2,011K
Depreciation
$1,851K
Direct program
expenses, other clinical...
$717K
Back
Back
Cash Flow
OCULAR THERAPEUTIX, INC (OCUL)
OCULAR THERAPEUTIX, INC (OCUL)
source: myfinsight.com